Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481284 | 1.00 | PTPN1 (0.38) | PTPN1PTGDR2MAPTGAAALDH1A1 | |
| SCHEMBL12829209 | 0.91 | FFAR4 (0.40) | PTPN1MAPTGAAALDH1A1MAPK1 | |
| SCHEMBL1480949 | 0.91 | PTGDR2 (0.43) | PTGDR2FFAR1 | |
| SCHEMBL1480954 | 0.91 | PTGDR2 (0.43) | PTGDR2FFAR1 | |
| SCHEMBL1481014 | 0.88 | PPARA (0.42) | MAPTGAAALDH1A1MAPK1RAB9A | |
| SCHEMBL1481018 | 0.88 | PPARA (0.42) | MAPTGAAALDH1A1MAPK1RAB9A | |
| SCHEMBL1481791 | 0.87 | LPAR2 (0.42) | PTGDR2MAPTGAAALDH1A1MAPK1 | |
| SCHEMBL1481793 | 0.87 | LPAR2 (0.42) | PTGDR2MAPTGAAALDH1A1MAPK1 | |
| SCHEMBL1480765 | 0.87 | MEN1 (0.37) | PTGDR2MAPTGAAALDH1A1RAB9A | |
| SCHEMBL1480762 | 0.87 | MEN1 (0.37) | PTGDR2MAPTGAAALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | PTPN1 10/4885PTGDR2 1829/4885MAPT 3558/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | PTPN1 10/4885PTGDR2 1829/4885MAPT 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.